Bibliography: library/10665-360861

The reference for library/10665-360861 (who-iris) and any references extracted from it. library · All references.

Export these 112 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

112 shown

  1. World Health Organization (2022). Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance: technical brief. World Health Organization.
    10665-360861 · catalogue · link · repository record · ISBN 9789240053694 (electronic version) · source: catalogue/records/10665-360861.dc.json · held: library/10665-360861
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Schaefer R, Schmidt HMA, Ravasi G, Mozalevskis A, Rewari BB, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8(8):e502-e510. doi:10.1016/S2352-3018(21)00127-2
    · extracted · doi:10.1016/S2352-3018(21)00127-2 · source: references/10665-360861.sec-030.1.json
  3. Political declaration on HIV and AIDS: ending inequalities and getting on track to end aids by 2030. New York City, NY: United Nations General Assembly; 2021 (https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.2.json
  4. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/rest/bitstreams/1451670/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.3.json
  5. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.4.json
  6. Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/360869, accessed 11 August 2022).
    · extracted · link · source: references/10665-360861.sec-030.5.json · held: library/10665-360869
  7. What’s the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/rest/bitstreams/1239070/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.6.json
  8. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-2246. doi:10.1056/NEJMoa1506273
    · extracted · doi:10.1056/NEJMoa1506273 · source: references/10665-360861.sec-030.7.json
  9. Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402-e410. doi:10.1016/S2352-3018(17)30089-9
    · extracted · doi:10.1016/S2352-3018(17)30089-9 · source: references/10665-360861.sec-030.8.json
  10. Hiransuthikul A, Janamnuaysook R, Himmad K, Kerr SJ, Thammajaruk N, Pankam T, et al. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc. 2019;22(7):e25338-e25338. doi:10.1002/jia2.25338
    · extracted · doi:10.1002/jia2.25338 · source: references/10665-360861.sec-030.9.json
  11. Shieh E, Marzinke MA, Fuchs EJ, Hamlin A, Bakshi R, Aung W, et al. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc. 2019;22(11):e25405. doi:10.1002/jia2.25405.
    · extracted · doi:10.1002/jia2.25405 · source: references/10665-360861.sec-030.10.json
  12. Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, et al. Sex hormone therapy and tenofovir diphosphate concentration in dried blood spots: primary results of the interactions between antiretrovirals and transgender hormones study. Clin Infect Dis. 2021;73(7):e2117-e2123. doi:10.1093/cid/ciaa1160
    · extracted · doi:10.1093/cid/ciaa1160 · source: references/10665-360861.sec-030.11.json
  13. Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55-64. doi:10.1093/infdis/jiw077
    · extracted · doi:10.1093/infdis/jiw077 · source: references/10665-360861.sec-030.12.json
  14. Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, et al. A pharmacokinetic/pharmacodynamic model to predict effective HIV prophylaxis dosing strategies for people who inject drugs. J Pharmacol Exp Ther. 2018;367(2):245-251. doi:10.1124/jpet.118.251009
    · extracted · doi:10.1124/jpet.118.251009 · source: references/10665-360861.sec-030.13.json
  15. Glidden DV, Anderson PL, Grant RM. Pharmacology supports on-demand PrEP. Lancet HIV. 2016;3(9):e405-e406. doi:10.1016/S2352-3018(16)30114-X
    · extracted · doi:10.1016/S2352-3018(16)30114-X · source: references/10665-360861.sec-030.14.json
  16. Iannuzzi S, von Kleist M. Mathematical modelling of the molecular mechanisms of interaction of tenofovir with emtricitabine against HIV. Viruses. 2021;13(7):1354. doi:10.3390/v13071354
    · extracted · doi:10.3390/v13071354 · source: references/10665-360861.sec-030.15.json
  17. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4-112re4. doi:10.1126/scitranslmed.3003174
    · extracted · doi:10.1126/scitranslmed.3003174 · source: references/10665-360861.sec-030.16.json
  18. Dickinson L, Yapa HM, Jackson A, Moyle G, Else L, Amara A, et al. Plasma tenofovir, emtricitabine, and rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics following drug intake cessation. Antimicrob Agents Chemother. 2015;59(10):6080-6086. doi:10.1128/AAC.01441-15
    · extracted · doi:10.1128/AAC.01441-15 · source: references/10665-360861.sec-030.17.json
  19. Cottrell ML, Srinivas N, Kashuba ADM. Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol. 2015;11(6):893-905. doi:10.1517/17425255.2015. 1027682
    · extracted · doi:10.1517/17425255.2015 · source: references/10665-360861.sec-030.18.json
  20. Duwal S, Sunkara V, von Kleist M. Multiscale systems-pharmacology pipeline to assess the prophylactic efficacy of NRTIs against HIV-1. CPT Pharmacometrics Syst Pharmacol. 2016;5(7):377-387. doi:10.1002/psp4.12095
    · extracted · doi:10.1002/psp4.12095 · source: references/10665-360861.sec-030.19.json
  21. Ford N, Irvine C, Shubber Z, Baggaley R, Beanland R, Vitoria M, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS. 2014;28(18). doi:10.1097/QAD.0000000000000505
    · extracted · doi:10.1097/QAD.0000000000000505 · source: references/10665-360861.sec-030.20.json
  22. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel. JAMA. 2020;324(16):1651-1669. doi:10.1001/jama.2020.17025
    · extracted · doi:10.1001/jama.2020.17025 · source: references/10665-360861.sec-030.21.json
  23. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. Letchworth; Macclesfield: British HIV Association (BHIVA); British Association for Sexual Health and HIV (BASHH); 2018 (https://www.bhiva.org/PrEP-guidelines, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.22.json
  24. EACS guidelines version 11.0, October 2021. Brussels: European AIDS Clinical Society (EACS); 2021 (https://www.eacsociety.org/guidelines/eacs-guidelines/, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.23.json
  25. Preexposure prophylaxis for the prevention of HIV infection in the United States–2021 update: a clinical practice guideline. Atlanta: Centers for Disease Control and Prevention: US Public Health Service; 2021 (https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.24.json
  26. World Health Organization. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec. 2017;92(27):369–392. (https://apps.who.int/iris/handle/10665/255873, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.25.json
  27. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/rest/bitstreams/688548/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.26.json
  28. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and HCV diagnostics. Geneva: World Health Organization; 2022.
    · extracted · source: references/10665-360861.sec-030.27.json
  29. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/bitstream/handle/10665/360601/9789240052390-eng.pdf, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.28.json · held: library/10665-360601
  30. Recommendations and guidance on hepatitis C virus self-testing. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/rest/bitstreams/1356715/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.29.json
  31. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/rest/bitstreams/1141441/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.30.json
  32. Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016–2021: actions for impact. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/rest/bitstreams/1348210/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.31.json
  33. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/rest/bitstreams/1031495/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.32.json
  34. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27-e27. doi:10.1371/journal.pctr.0020027
    · extracted · doi:10.1371/journal.pctr.0020027 · source: references/10665-360861.sec-030.33.json
  35. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599. doi:10.1056/NEJMoa1011205
    · extracted · doi:10.1056/NEJMoa1011205 · source: references/10665-360861.sec-030.34.json
  36. Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira J V, Hance RJ, et al. The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B. J Acquir Immune Defic Syndr. 2016;71(3):281-286. doi:10.1097/QAI.0000000000000857
    · extracted · doi:10.1097/QAI.0000000000000857 · source: references/10665-360861.sec-030.35.json
  37. Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol. 2020;5(4):406-417. doi:10.1016/S2468-1253(19)30344-9
    · extracted · doi:10.1016/S2468-1253(19)30344-9 · source: references/10665-360861.sec-030.36.json
  38. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434-442. doi:10.1002/hep.26686
    · extracted · doi:10.1002/hep.26686 · source: references/10665-360861.sec-030.37.json
  39. Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24(1):68-74. doi:10.1111/jvh.12613
    · extracted · doi:10.1111/jvh.12613 · source: references/10665-360861.sec-030.38.json
  40. Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39(10):1868-1875. doi:10.1111/liv.14155
    · extracted · doi:10.1111/liv.14155 · source: references/10665-360861.sec-030.39.json
  41. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/333391/9789240002708-eng.pdf, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.40.json
  42. Diagnosis and management of type 2 diabetes (HEARTS D). Geneva: World Health Organization; 2020 (https://apps.who.int/iris/rest/bitstreams/1274478/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.41.json
  43. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953
    · extracted · doi:10.1056/NEJMoa2102953 · source: references/10665-360861.sec-030.42.json
  44. Patel N, Blumenthal J, Dubé MP, Hood A, Bolan R, Morris S. Method of calculating renal function estimates could inappropriately exclude transgender patients receiving gender-affirming hormone therapy from pre-exposure prophylaxis eligibility. LGBT Health. 2022;9(3):199-206. doi:10.1089/lgbt.2021.0219
    · extracted · doi:10.1089/lgbt.2021.0219 · source: references/10665-360861.sec-030.43.json
  45. Webb AJ, McManus D, Rouse GE, Vonderheyde R, Topal JE. Implications for medication dosing for transgender patients: a review of the literature and recommendations for pharmacists. Am J Health Syst Pharm. 2020;77(6):427-433. doi:10.1093/ajhp/zxz355
    · extracted · doi:10.1093/ajhp/zxz355 · source: references/10665-360861.sec-030.44.json
  46. Gao M, Vilayur E, Ferreira D, Nanra R, Hawkins J. Estimating the glomerular filtration rate in pregnancy: the evaluation of the Nanra and CKD-EPI serum creatinine-based equations. Obstet Med. 2021;14(1):31-34. doi:10.1177/1753495X20904177
    · extracted · doi:10.1177/1753495X20904177 · source: references/10665-360861.sec-030.45.json
  47. Schaefer R, Amparo da Costa Leite PH, Silva R, Abdool Karim Q, Akolo C, Cáceres CF, et al. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. Lancet HIV. 2022;9(4):e242-e253. doi:10.1016/S2352-3018(22)00004-2
    · extracted · doi:10.1016/S2352-3018(22)00004-2 · source: references/10665-360861.sec-030.46.json
  48. Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad. 2018;4(4):215-224. doi:10.1016/S2055-6640(20)30312-5
    · extracted · doi:10.1016/S2055-6640(20)30312-5 · source: references/10665-360861.sec-030.47.json
  49. Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321(22):2214-2230. doi:10.1001/jama.2019.2591
    · extracted · doi:10.1001/jama.2019.2591 · source: references/10665-360861.sec-030.48.json
  50. Technical Specifications Series for submission to WHO prequalification – Diagnostic assessment: human immunodeficiency virus (HIV) rapid diagnostic tests for professional use and/or self-testing. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/bitstream/handle/10665/251857/9789241511742-eng.pdf, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.49.json
  51. Figueroa C, Johnson C, Ford N, Sands A, Dalal S, Meurant R, et al. Reliability of HIV rapid diagnostic tests for self-testing compared with testing by health-care workers: a systematic review and meta-analysis. Lancet HIV. 2018;5(6):e277-e290. doi:10.1016/S2352-3018(18)30044-4
    · extracted · doi:10.1016/S2352-3018(18)30044-4 · source: references/10665-360861.sec-030.50.json
  52. Maintaining essential health services: operational guidance for the COVID-19 context. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/rest/bitstreams/1279080/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.51.json
  53. Kiptinness C, Kuo A, Reedy A, Johnson C, Ngure K, Wagner A, et al. Examining the use of HIV self-testing to support PrEP delivery: a systematic literature review. 2022 [Submitted].
    · extracted · source: references/10665-360861.sec-030.52.json
  54. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 10: testing. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/bitstream/handle/10665/258516/WHO-HIV-2017.30-eng.pdf?sequence=1, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.53.json · held: library/10665-258516
  55. Shahmanesh M, Mthiyane TN, Herbsst C, Neuman M, Adeagbo O, Mee P, et al. Effect of peer-distributed HIV self-test kits on demand for biomedical HIV prevention in rural Kwazulu-Natal, South Africa: a three-armed cluster-randomised trial comparing social networks versus direct delivery. BMJ Glob Health. 2021;6(Suppl 4):e004574. doi:10.1136/bmjgh-2020-004574
    · extracted · doi:10.1136/bmjgh-2020-004574 · source: references/10665-360861.sec-030.54.json
  56. Adeagbo OA, Seeley J, Gumede D, Xulu S, Dlamini N, Luthuli M, et al. Process evaluation of peer-to-peer delivery of HIV self-testing and sexual health information to support HIV prevention among youth in rural Kwazulu-Natal, South Africa: qualitative analysis. BMJ Open. 2022;12(2):e048780-e048780. doi:10.1136/bmjopen-2021-048780
    · extracted · doi:10.1136/bmjopen-2021-048780 · source: references/10665-360861.sec-030.55.json
  57. HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/rest/bitstreams/1315098/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.56.json
  58. Sanders EJ, Wahome E, Powers KA, Werner L, Fegan G, Lavreys L, et al. Targeted screening of at-risk adults for acute HIV-1 infection in sub-Saharan Africa. AIDS. 2015;29 Suppl 3(0 3):S221-S230. doi:10.1097/QAD.0000000000000924
    · extracted · doi:10.1097/QAD.0000000000000924 · source: references/10665-360861.sec-030.57.json
  59. Phillips AN, Bershteyn A, Revill P, Bansi-Matharu L, Kripke K, Boily MC, et al. Cost– effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022;9(5):e353-e362. doi:10.1016/S2352-3018(22)00029-7
    · extracted · doi:10.1016/S2352-3018(22)00029-7 · source: references/10665-360861.sec-030.58.json
  60. Consolidated guidelines on HIV testing services, 2019. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/rest/bitstreams/1313903/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.59.json
  61. Kerzner M, De AK, Yee R, Keating R, Djomand G, Stash S, et al. Pre-exposure prophylaxis (PrEP) uptake and service delivery adaptations during the first wave of the COVID-19 pandemic in 21 PEPFAR-funded countries. PLoS One. 2022;17(4):e0266280. doi:10.1371/journal.pone.0266280
    · extracted · doi:10.1371/journal.pone.0266280 · source: references/10665-360861.sec-030.60.json
  62. Key considerations in developing policy guidance for differentiated PrEP service delivery: country policy development brief. Geneva: International AIDS Society; 2022 (https://www.differentiatedservicedelivery.org/Resources/Resource-Library/DSD-PrEP-policy-2022, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.61.json
  63. Tittle V, Dalton R, Nugent D, Girometti N, Whitlock G, Mcowan A, et al. Complex PrEP: the factors requiring consultant-led review of PrEP users. Sex Transm Infect. Published online February 15, 2022:sextrans-2021-055277. doi:10.1136/sextrans-2021-055277
    · extracted · doi:10.1136/sextrans-2021-055277 · source: references/10665-360861.sec-030.62.json
  64. Velloza J, Schaefer R, Dalal S, Michelle R, Baggaley R. Evidence on acceptability, feasibility, and effectiveness of community-based delivery of HIV pre-exposure prophylaxis: results from a systematic review. Presented at: Adherence 2022, 11–13 July 2022, Washington, DC, USA.
    · extracted · source: references/10665-360861.sec-030.63.json
  65. Rousseau E, Bekker LG, Julies RF, Celum C, Morton J, Johnson R, et al. A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa. BMC Health Serv Res. 2021;21(1):888. doi:10.1186/s12913-021-06920-4
    · extracted · doi:10.1186/s12913-021-06920-4 · source: references/10665-360861.sec-030.64.json
  66. Rosecrans A, Harris R, Saxton RE, Cotterell M, Zoltick M, Willman C, et al. Mobile low-threshold bupenorphrine integrated with infectious disease services. J Subst Abuse Treat. 2022;133. doi:10.1016/j.jsat.2021.108553
    · extracted · doi:10.1016/j.jsat.2021.108553 · source: references/10665-360861.sec-030.65.json
  67. Grammatico MA, Moll AP, Choi K, Springer SA, Shenoi S V. Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South Africa. J Int AIDS Soc. 2021;24(11):e25848-e25848. doi:10.1002/jia2.25848
    · extracted · doi:10.1002/jia2.25848 · source: references/10665-360861.sec-030.66.json
  68. Hoagland B, Torres TS, Bezerra DRB, Geraldo K, Pimenta C, Veloso VG, et al. Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in a large HIV prevention service in Rio de Janeiro-Brazil. Brazilian J Infect Dis. 2020;24(4):360-364. doi:10.1016/j.bjid.2020.05.004
    · extracted · doi:10.1016/j.bjid.2020.05.004 · source: references/10665-360861.sec-030.67.json
  69. Dourado I, Magno L, Soares F, Massa P, Nunn A, Dalal S, et al. Adapting to the COVID-19 pandemic: continuing HIV prevention services for adolescents through telemonitoring, Brazil. AIDS Behav. 2020;24(7):1994-1999. doi:10.1007/s10461-020-02927-w
    · extracted · doi:10.1007/s10461-020-02927-w · source: references/10665-360861.sec-030.68.json
  70. Hoagland B, Torres TS, Bezerra DRB, Benedetti M, Pimenta C, Veloso VG, et al. High acceptability of PrEP teleconsultation and HIV self-testing among PrEP users during the COVID-19 pandemic in Brazil. Brazilian J Infect Dis. 2021;25(1):101037. doi:10.1016/j.bjid.2020.11.002
    · extracted · doi:10.1016/j.bjid.2020.11.002 · source: references/10665-360861.sec-030.69.json
  71. Magno L. How to keep the innovation in the era of COVID-19 – Leaving adults out of the equation: using chatbots to provide interactive information to adolescents and young adults. Presented at: HIVR4P, 27–28 January & 3–4 February 2021, virtual (https://programme.hivr4p.org/Programme/Session/51, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.70.json
  72. Pascom A. Impact of COVID-19 pandemic on HIV care in Brazil. Presented at: CROI, 6–11 March 2021, virtual (https://www.croiconference.org/abstract/impact-of-covid-19-pandemic-on-hiv-care-in-brazil/, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.71.json
  73. The role of the pharmacist in self-care and self-medication. Geneva: World Health Organization; 1998 (https://apps.who.int/iris/handle/10665/65860, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.72.json
  74. Ortblad KF, Mogere P, Bukusi E, Ngure K, Baeten JM. Pharmacy delivery to expand the reach of PrEP in Africa. J Int AIDS Soc. 2020;23(9):e25619. doi:10.1002/jia2.25619
    · extracted · doi:10.1002/jia2.25619 · source: references/10665-360861.sec-030.73.json
  75. WHO guideline on self-care interventions for health and well-being. Geneva: World Health Organization (https://apps.who.int/iris/rest/bitstreams/1440452/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.74.json
  76. Kennedy CE, Yeh PT, Atkins K, Ferguson L, Baggaley R, Narasimhan M. PrEP distribution in pharmacies: a systematic review. BMJ Open. 2022;12(2):e054121-e054121. doi:10.1136/bmjopen-2021-054121
    · extracted · doi:10.1136/bmjopen-2021-054121 · source: references/10665-360861.sec-030.75.json
  77. Zhao A, Dangerfield DT, Nunn A, Patel R, Farley JE, Ugoji CC, et al. Pharmacy-based interventions to increase use of HIV pre-exposure prophylaxis in the United States: a scoping review. AIDS Behav. 2022;26(5):1377-1392. doi:10.1007/s10461-021-03494-4
    · extracted · doi:10.1007/s10461-021-03494-4 · source: references/10665-360861.sec-030.76.json
  78. Vanhamel J, Rotsaert A, Reyniers T, Nöstlinger C, Laga M, Van Landeghem E, et al. The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review. BMC Health Serv Res. 2020;20(1):704. doi:10.1186/s12913-020-05568-w
    · extracted · doi:10.1186/s12913-020-05568-w · source: references/10665-360861.sec-030.77.json
  79. Schmidt HMA, Schaefer R, Nguyen VTT, Radebe M, Sued O, Rodolph M, et al. Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job? Lancet HIV. 2022;9(5):e363-e366. doi:10.1016/S2352-3018(22)00006-6
    · extracted · doi:10.1016/S2352-3018(22)00006-6 · source: references/10665-360861.sec-030.78.json
  80. Vannakit R, Janyam S, Linjongrat D, Chanlearn P, Sittikarn S, Pengnonyang S, et al. Give the community the tools and they will help finish the job: key population-led health services for ending AIDS in Thailand. J Int AIDS Soc. 2020;23(6):e25535. doi:10.1002/jia2.25535
    · extracted · doi:10.1002/jia2.25535 · source: references/10665-360861.sec-030.79.json
  81. Phanuphak N, Sungsing T, Jantarapakde J, Pengnonyang S, Trachunthong D, Mingkwanrungruang P, et al. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. Sex Health. 2018;15(6):542-555. doi:10.1071/sh18065
    · extracted · doi:10.1071/sh18065 · source: references/10665-360861.sec-030.80.json
  82. Green KE, Nguyen LH, Phan HTT, Vu BN, Tran MH, Ngo H Van, et al. Prepped for PrEP? Acceptability, continuation and adherence among men who have sex with men and transgender women enrolled as part of Vietnam’s first pre-exposure prophylaxis program. Sex Health. 2021;18(1):104-115. doi:10.1071/SH20167
    · extracted · doi:10.1071/SH20167 · source: references/10665-360861.sec-030.81.json
  83. Matambanadzo P, Busza J, Mafaune H, Chinyanganya L, Machingura F, Ncube G, et al. “It went through the roof”: an observation study exploring the rise in PrEP uptake among Zimbabwean female sex workers in response to adaptations during Covid-19. J Int AIDS Soc. 2021;24(S6):e25813. doi:10.1002/jia2.25813
    · extracted · doi:10.1002/jia2.25813 · source: references/10665-360861.sec-030.82.json
  84. Bailey LE, Siberry GK, Agaba P, Douglas M, Clinkscales JR, Godfrey C. The impact of COVID-19 on multi-month dispensing (MMD) policies for antiretroviral therapy (ART) and MMD uptake in 21 PEPFAR-supported countries: a multi-country analysis. J Int AIDS Soc. 2021;24(S6):e25794. doi:10.1002/jia2.25794
    · extracted · doi:10.1002/jia2.25794 · source: references/10665-360861.sec-030.83.json
  85. A rapid assessment of multi-month dispensing of antiretroviral treatment and pre-exposure prophylaxis [in] the Asia-Pacific region. Bangkok: UNAIDS Regional Office for Asia and the Pacific; 2020 (https://www.aidsdatahub.org/sites/default/files/resource/unaids-ap-rapid-assessment-mmd-implementation-asia-and-pacific-2020.pdf, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.84.json
  86. Rapid guidance on HIV service delivery in COVID-19 context. Harare: Zimbabwe Ministry of Health and Child Care; 2020
    · extracted · source: references/10665-360861.sec-030.85.json
  87. Ngure K. Six-month PrEP with HIV self-testing to improve delivery Kenya: a randomized trial. Presented at: CROI, 12–16 February 2022, virtual (https://www.croiconference.org/abstract/six-month-prep-with-hiv-self-testing-to-improve-delivery-kenya-a-randomized-trial/, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.86.json
  88. Sewell WC, Powell VE, Ball-Burack M, Mayer KH, Ochoa A, Marcus JL, et al. Brief report: “i didn’t really have a primary care provider until I got PrEP”: patients’ perspectives on HIV preexposure prophylaxis as a gateway to health care. J Acquir Immune Defic Syndr. 2021;88(1):31-35. doi:10.1097/QAI.0000000000002719
    · extracted · doi:10.1097/QAI.0000000000002719 · source: references/10665-360861.sec-030.87.json
  89. Phanuphak N, Ramautarsing R, Chinbunchorn T, Janamnuaysook R, Pengnonyang S, Termvanich K, et al. Implementing a status-neutral approach to HIV in the Asia-Pacific. Curr HIV/AIDS Rep. 2020;17(5):422-430. doi:10.1007/s11904-020-00516-z
    · extracted · doi:10.1007/s11904-020-00516-z · source: references/10665-360861.sec-030.88.json
  90. Myers JE, Braunstein SL, Xia Q, Scanlin K, Edelstein Z, Harriman G, et al. Redefining prevention and care: a status-neutral approach to HIV. Open Forum Infect Dis. 2018;5(6):ofy097-ofy097. doi:10.1093/ofid/ofy097
    · extracted · doi:10.1093/ofid/ofy097 · source: references/10665-360861.sec-030.89.json
  91. Integration of mental health and HIV interventions – Key considerations. Geneva: Joint United Nations Programme on HIV/AIDS; World Health Organization; 2022 (https://www.unaids.org/en/resources/documents/2022/integration-mental-health-hiv-interventions, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.90.json
  92. van Griensven F, Janamnuaysook R, Nampaisan O, Peelay J, Samitpol K, Mills S, et al. Uptake of primary care services and HIV and syphilis infection among transgender women attending the Tangerine Community Health Clinic, Bangkok, Thailand, 2016–2019. J Int AIDS Soc. 2021;24(6):e25683-e25683. doi:10.1002/jia2.25683
    · extracted · doi:10.1002/jia2.25683 · source: references/10665-360861.sec-030.91.json
  93. Sevelius J. Factors affecting PrEP uptake and time to initiation among transgender participants in the TRIUMPH PrEP demonstration project in Oakland and Sacramento, California. Presented at: 23rd International AIDS Conference, 6–10 July 2020, San Francisco (virtual) (http://programme.aids2020.org/Abstract/Abstract/3391, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.92.json
  94. Green K. Transforming PrEP in Vietnam: rethinking service delivery to enhance access among transgender women. Presented at: 23rd International AIDS Conference, 6–10 July 2020, San Francisco, CA, USA (virtual) (http://programme.aids2020.org/Programme/Session/71, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.93.json
  95. Preventing HIV and other STIs among women and girls using contraceptive services in contexts with high HIV incidence. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/rest/bitstreams/1279661/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.94.json
  96. Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya. PLOS Med. 2019;16(9):e1002885. doi:10.1371/journal.pmed.1002885
    · extracted · doi:10.1371/journal.pmed.1002885 · source: references/10665-360861.sec-030.95.json
  97. Wanga V, Peebles K, Obiero A, Mogaka F, Omollo V, Odoyo JB, et al. Cost of pre-exposure prophylaxis delivery in family planning clinics to prevent HIV acquisition among adolescent girls and young women in Kisumu, Kenya. PLoS One. 2021;16(4):e0249625-e0249625. doi:10.1371/journal.pone.0249625
    · extracted · doi:10.1371/journal.pone.0249625 · source: references/10665-360861.sec-030.96.json
  98. Bhavaraju N, Wilcher R, Regeru RN, Mullick S, Mahaka I, Rodrigues J, et al. Integrating oral PrEP into family planning services for women in sub-Saharan Africa: findings from a multi-country landscape analysis. Front Reprod Health. 2021;3. doi:10.3389/frph.2021.667823
    · extracted · doi:10.3389/frph.2021.667823 · source: references/10665-360861.sec-030.97.json
  99. Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(12):e1917134-e1917134. doi:10.1001/jamanetworkopen.2019.17134
    · extracted · doi:10.1001/jamanetworkopen.2019.17134 · source: references/10665-360861.sec-030.98.json
  100. Prevention and control of sexually transmitted infections (STIs) in the era of oral pre-exposure prophylaxis (PrEP) for HIV. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/rest/bitstreams/1238572/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.99.json
  101. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/rest/bitstreams/1315304/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.100.json
  102. Ong JJ, Fu H, Baggaley RC, Wi TE, Tucker JD, Smith MK, et al. Missed opportunities for sexually transmitted infections testing for HIV pre-exposure prophylaxis users: a systematic review. J Int AIDS Soc. 2021;24(2):e25673. doi:10.1002/jia2.25673
    · extracted · doi:10.1002/jia2.25673 · source: references/10665-360861.sec-030.101.json
  103. WHO information note on the use of dual HIV/syphilis rapid diagnostic tests (RDT). Geneva: World Health Organization; 2017 (https://apps.who.int/iris/bitstream/handle/10665/252849/WHO-RHR-17.01-eng.pdf?sequence=1, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.102.json
  104. Dual HIV/syphilis rapid diagnostic tests can be used as the first test in antenatal care. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/rest/bitstreams/1261480/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.103.json
  105. Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/rest/bitstreams/1355614/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.104.json
  106. Self-collection of samples for sexually transmitted infections (STIs). Geneva: World Health Organization; 2020 (https://apps.who.int/iris/rest/bitstreams/1280120/retrieve, accessed 29 June 2022).
    · extracted · link · source: references/10665-360861.sec-030.105.json
  107. Kersh EN, Shukla M, Raphael BH, Habel M, Park I. At-home specimen self-collection and self-testing for sexually transmitted infection screening demand accelerated by the COVID-19 pandemic: a review of laboratory implementation issues. J Clin Microbiol. 2022;59(11):e02646-20. doi:10.1128/JCM.02646-20
    · extracted · doi:10.1128/JCM.02646-20 · source: references/10665-360861.sec-030.106.json
  108. Hiransuthikul A, Janamnuaysook R, Himma L, Taya C, Amatsombat T, Chumnanwet P, et al. Acceptability and satisfaction towards self-collection for chlamydia and gonorrhoea testing among transgender women in Tangerine Clinic, Thailand: shifting towards the new normal. J Int AIDS Soc. 2021;24(9):e25801-e25801. doi:10.1002/jia2.25801
    · extracted · doi:10.1002/jia2.25801 · source: references/10665-360861.sec-030.107.json
  109. Grimshaw C, Boyd L, Smith M, Estcourt CS, Metcalfe R. Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs. HIV Med. 2021;22(10):965-970. doi:10.1111/hiv.13181
    · extracted · doi:10.1111/hiv.13181 · source: references/10665-360861.sec-030.108.json
  110. McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6(5):e315-e324. doi:10.1016/S2352-3018(19)30036-0
    · extracted · doi:10.1016/S2352-3018(19)30036-0 · source: references/10665-360861.sec-030.109.json
  111. Metcalfe R, Ragonnet-Cronin M, Bradley-Stewart A, McAuley A, Stubbs H, Ritchie T, et al. From hospital to the community: redesigning the human immunodeficiency virus (HIV) clinical service model to respond to an outbreak of HIV among people who inject drugs. J Infect Dis. 2020;222(Suppl 5):S410-S419. doi:10.1093/infdis/jiaa336
    · extracted · doi:10.1093/infdis/jiaa336 · source: references/10665-360861.sec-030.110.json
  112. Smith M, Elliott L, Hutchinson SJ, Metcalfe R, Flowers P, McAuley A. Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an HIV outbreak: a qualitative study. Int J Drug Policy. 2021;88:103033. doi:10.1016/j.drugpo.2020.103033
    · extracted · doi:10.1016/j.drugpo.2020.103033 · source: references/10665-360861.sec-030.111.json